Loading
Latest filing published 01 Feb 2022 for HOOKIPA Pharma Inc., €40k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Igor Matushansky in HOOKIPA Pharma Inc., where the filings describe the role as chief executive. Between 21 December 2021 and 1 February 2022, the trades on record add up to 2 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 1 February 2022, the filings show a share grant worth €40k in HOOKIPA Pharma Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations